Long-acting injectable therapy

PURPOSE OF REVIEW: Long-acting formulations of antiretrovirals have the potential to reshape the treatment paradigm for HIV infection. Emerging evidence demonstrates efficacy and safety of two drug regimens for the treatment of HIV infection. This review focuses on recent advances with long-acting cabotegravir and rilpivirine administered intramuscularly every 4 weeks for the treatment of HIV infection in virologically suppressed patients. RECENT FINDINGS: Despite the development of complete, orally administered single tablet regimens with improved efficacy, side effects, tolerability, with an improved drug interaction potential, patients still have challenges adhering to daily oral therapy. Psychological factors including HIV stigma contribute to patient's ability to adhere to treatment. Newer nonoral treatment regimens may improve adherence, patient satisfaction and limit HIV stigma. SUMMARY: A two-drug intramuscular regimen of cabotegravir and rilpivirine has advanced through phase 3 clinical development. Results from studies assessing safety, virologic, pharmacologic, and drug interactions have been completed. Larger efficacy studies have demonstrated noninferiority of switching virologically suppressed patients from a three drug daily oral regimen to a two-drug intramuscular regimen administered Q4W with long-term data to 160 weeks demonstrating durability of treatment response.